TR
TRL.F DaVita Inc
- Market cap
- EUR 9.93B
- P/E
- 13.9x
- P/B
- 21.60x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is TRL.F undervalued?
Graham numberThe Graham number of DaVita Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DaVita Inc fundamental analysis
No fundamental analysis for DaVita Inc yet.
DaVita Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DaVita Inc
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and ma…
Full company profileDaVita Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
DaVita Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 14.7B | 10.9B | 11.4B | 11.4B | 11.6B | 11.6B | 11.6B | 12.1B | 12.8B | 13.6B | 14.1B |
| Gross Profit | 4.10B | 3.24B | 3.21B | 3.47B | 3.56B | 3.65B | 3.40B | 3.82B | 4.22B | 4.40B | 4.48B |
| Operating Income | 1.77B | 1.62B | 1.49B | 1.76B | 1.68B | 1.77B | 1.31B | 1.60B | 1.95B | 2.01B | 2.13B |
| EBITDA | - | 2.61B | 2.13B | 2.25B | 2.25B | 2.48B | 2.06B | 2.32B | 2.72B | 2.64B | 2.79B |
| Net Income | 880M | 664M | 159M | 811M | 774M | 978M | 560M | 692M | 936M | 747M | 914M |
| EPS | - | 3.64 | 0.96 | 6.44 | 7.04 | 10 | 6.20 | 7.79 | 12 | 11 | 14 |
| Balance Sheet | |||||||||||
| Total Assets | 18.7B | 18.9B | 19.1B | 17.3B | 17.0B | 17.1B | 16.9B | 16.9B | 17.3B | 17.5B | 17.8B |
| Total Liabilities | 13.9B | 14.1B | 15.2B | 15.0B | 15.4B | 16.2B | 14.7B | 14.2B | 15.2B | 16.3B | 16.7B |
| Shareholders' Equity | 4.65B | 4.69B | 3.70B | 2.13B | 1.38B | 756M | 712M | 1.06B | 121M | -651M | -591M |
| Cash & Short-term Investments | 913M | 508M | 323M | 1.10B | 325M | 462M | 244M | 380M | 795M | 676M | 496M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.99B | 1.97B | 1.53B | 2.50B | 1.98B | 1.93B | 1.56B | 1.92B | 2.02B | 1.89B | 1.77B |
| Capital Expenditure | 829M | 905M | 987M | 767M | 675M | 641M | 603M | 603M | 555M | 576M | 575M |
| Free Cash Flow | - | 1.00B | 785M | 1.31B | 1.30B | 1.29B | 961M | 1.31B | 1.47B | 1.31B | 1.20B |
| Ratios | |||||||||||
| ROE | 18.9% | 14.1% | 4.3% | 38.0% | 55.9% | 129.5% | 78.7% | 65.5% | 773.1% | - | - |
| ROA | 4.7% | 3.5% | 0.8% | 4.7% | 4.6% | 5.7% | 3.3% | 4.1% | 5.4% | 4.3% | 5.1% |
| Net Profit Margin | 6.0% | 6.1% | 1.4% | 7.1% | 6.7% | 8.4% | 4.8% | 5.7% | 7.3% | 5.5% | 6.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
DaVita Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | USD 211M | 1.16 | 31.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Sep 9, 2013.
Who owns DaVita Inc
- Insiders 46.97%
- Institutions 50.59%
- Public & others 2.44%
- Shares outstanding 62.9M
- Free float 33.4M
DaVita Inc company profile
- Company name
- DaVita Inc
- Ticker
- TRL.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 78,000
- Fiscal year end
- December
- Address
- 2000 16th Street, Denver, CO, United States, 80202
- Phone
- 720 631 2100
- Website
- davita.com
About DaVita Inc
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
DaVita Inc management
10- Mr. Javier J. RodriguezCEO & Executive Director · born 1971
- Mr. Joel AckermanCFO & Treasurer · born 1965
- Ms. Kathleen Alyce WatersChief Legal & Public Affairs Officer · born 1968
- Mr. James O. HeartyChief Compliance Officer · born 1969
- Mr. David P. MaughanChief Operating Officer of DaVita Kidney Care · born 1977
- Mr. Christopher Michael Berry CPAGroup VP & Chief Accounting Officer · born 1975
- Nic EliasonGroup Vice President of Investor Relations
- Ms. Stephanie HendricksonChief People Officer
- Mr. Misha PalecekChief Transformation Officer of U.S. Kidney Care Business
- Dr. Jeffrey Allen GiullianChief Medical Officer of Kidney Care